Medicinova, Inc.
MNOVMedicinnova, Inc. is a biotechnology company focused on developing novel therapeutics for rare and serious diseases. The company's research primarily targets conditions with limited treatment options, leveraging its expertise in drug discovery and development to bring innovative solutions to unmet medical needs.
Company News
MediciNova completed randomization of 234 patients in its COMBAT-ALS clinical trial for MN-166, a potential treatment for Amyotrophic Lateral Sclerosis. The company anticipates top-line data by end of 2026 and remains hopeful about the drug's therapeutic potential.
MediciNova published research demonstrating how its drug MN-001 potentially improves cholesterol transport and addresses metabolic disorders, with Phase 2 trial results expected in summer 2026.
MediciNova received the Contract Research and Development Innovation Award for its innovative work on MN-166, a small molecule drug candidate targeting neurological diseases like ALS, demonstrating promising therapeutic potential.
MediciNova completed enrollment for its COMBAT-ALS Phase 2b/3 clinical trial of MN-166, a potential treatment for Amyotrophic Lateral Sclerosis (ALS), marking a significant milestone in neurodegenerative disease research.
MediciNova secured a $30 million standby equity purchase agreement with Yorkville Advisors, allowing flexible capital raising over 36 months to support ongoing R&D programs without issuing warrants.
